Roche Digs Into Obesity-Tied Diseases With $3.5 Billion 89bio Buyout

investors.com/news/technology/roche-89bio-acquisition-mash-obesity

Small biotech 89bio nearly doubled Thursday after Roche agreed to buy the MASH drug developer in a deal worth up to $3.5 billion.
The post Roche Digs Into Obesity-Tied Diseases With $3.5 Billion 89bio Buyout appeared first on Investor's Business Daily.

This story appeared on investors.com, 2025-09-18 13:34:26.
The Entire Business World on a Single Page. Free to Use →